RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; and dilution of shareholding. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read FULL risk warning.
Beamline Diagnostics Ltd.
BeamLine, are developing a biopsy triaging system that can identify healthy and benign tissue specimens with high accuracy within seconds.
Investment closes only once the total pledged amount passes the minimum of £50,000
This Pledge is not a commitment. You will be asked to confirm in the next section.
TOTAL INVESTMENT ROUND: £650,000
INVESTMENT SOUGHT VIA DEEPBRIDGE EIS: £112,500
BeamLine Diagnostics is developing the Solas system which combines commercially available hardware with a patent-pending data analysis method to provide a rapid, accurate and low-cost system for screening biopsies point-of-care for pre-cancer/cancer.
The system can be used in routine biopsy clinics to provide multiple benefits:
diagnoses for healthy patients
money and resources on histopathology
the backlog in pathology laboratories.
The gold-standard method for diagnosing cancer is by taking a biopsy followed by microscopic analysis. This is a labour-intensive process that requires highly skilled technicians. In NHS England alone 1.14 million biopsy procedures were performed in 2012, each generating between 2 and 40 biopsies. There is a considerable backlog in the pathology labs for the analysis of these samples and most patients do not receive results for at least 2 weeks. However, over 90% of biopsy samples do not indicate the need for further action. The BeamLine system would allow biopsies to be simply screened at the bedside, identifying healthy patients within minutes. This would reduce the total number of samples sent to histology and give healthy patients peace of mind.
The technology uses infrared spectroscopy to reveal subtle differences between healthy and diseased samples. The absorbance of infrared (IR) light of different frequencies give information about the chemical composition of a sample. Using these spectral patterns, unique algorithms have been developed so that it is possible to detect subtle changes occurring in diseased samples and, hence, distinguish healthy samples from diseased.
BeamLine will initially target the gastrointestinal biopsy market, estimated to be worth at least £40M in NHS England alone. The GI biopsy market occupies two thirds of the biopsy market in the UK.
The patent-pending analytical software application works with a commercially available infrared spectrometer to quantify biochemical changes in pre-cancerous and cancerous tissue.
Angels in MedCity
Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. Angels in MedCity are the Lead investors in this £650,000 investment round.
Important Note: Responses to Q&A come directly from the Management Team and have not been authorised as part of an approved financial promotion. Click here for more information.